Want to see CELC full AI Analyst Report?
CELC Stock Chart & Stats
$122.46
-$0.35(-2.63%)
At close: 4:00 PM EST
$122.46
-$0.35(-2.63%)
Day’s Range― - ―
52-Week Range$13.31 - $151.02
Previous CloseN/A
Volume14.25K
Average Volume (3M)1.62M
Market Cap
$5.30B
Enterprise Value$4.34B
Total Cash (Recent Filing)$145.19M
Total Debt (Recent Filing)$195.58M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 06, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.89
Shares Outstanding48,766,290
10 Day Avg. Volume1,297,660
30 Day Avg. Volume1,620,062
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)52.11
Price to Sales (P/S)0.00
P/FCF Ratio-34.13
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-49.93K
Enterprise Value/Ebitda-25.16
Forecast
1Y Price Target
$161.75Price Target Upside32.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.03
Revenue Forecast (FY)$52.50M
Bulls Say, Bears Say
Bulls Say
Phase III Clinical Superiority In VIKTORIA-1Robust Phase III superiority versus an established PAM inhibitor demonstrates clinical differentiation likely to persist with adoption. A durable efficacy advantage can drive label expansion, stronger guideline and payer support, and sustainable market share in second-line HR+/HER2- breast cancer if confirmed at launch.
Fully Staffed, Experienced Commercial OrganizationA seasoned commercial team materially lowers launch execution risk and accelerates payer engagement. Long-tenured sales reps help secure formulary access and prescriber adoption, providing a structural advantage during rollout and supporting sustained uptake if regulatory approval is achieved.
Refinanced Debt To Extend Maturity And Improve LiquidityExtending debt maturities and replacing high-cost term loan with longer-dated convertibles meaningfully improves near- to medium-term liquidity and reduces refinancing risk. This structural funding relief supports clinical programs and commercial build-out through key regulatory readouts.
Bears Say
Substantial And Rising Cash BurnPersistently large negative operating and free cash flow creates structural dependence on external financing, increasing dilution risk and constraining discretionary investments. If capital markets tighten or conversion/dilution is resisted, clinical and commercial programs could face delays or reprioritization.
Elevated Leverage And Weakening Equity BaseA sharp increase in leverage and declining equity materially raises financial vulnerability. Higher fixed obligations reduce flexibility to fund trials or commercialization, amplify refinancing risk, and increase the probability management must pursue dilutive funding or restrictive covenants over the medium term.
Pre-revenue Profile With Long Regulatory And Development TimelinesNo commercial revenue today and multi-year timelines to broaden indications or complete formulation bridging mean prolonged cash consumption and delayed scale benefits. The elongated development horizon keeps meaningful revenue and operating leverage uncertain for several years, sustaining funding needs.
Celcuity News
CELC FAQ
What was Celcuity Inc.’s price range in the past 12 months?
Celcuity Inc. lowest stock price was $13.31 and its highest was $151.02 in the past 12 months.
What is Celcuity Inc.’s market cap?
Celcuity Inc.’s market cap is $5.30B.
When is Celcuity Inc.’s upcoming earnings report date?
Celcuity Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 29 days.
How were Celcuity Inc.’s earnings last quarter?
Celcuity Inc. released its earnings results on May 14, 2026. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.04 by $0.07.
Is Celcuity Inc. overvalued?
According to Wall Street analysts Celcuity Inc.’s price is currently Undervalued.
Does Celcuity Inc. pay dividends?
Celcuity Inc. does not currently pay dividends.
What is Celcuity Inc.’s EPS estimate?
Celcuity Inc.’s EPS estimate is -1.11.
How many shares outstanding does Celcuity Inc. have?
Celcuity Inc. has 48,766,290 shares outstanding.
What happened to Celcuity Inc.’s price movement after its last earnings report?
Celcuity Inc. reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.04. Following the earnings report the stock price went up 2.197%.
Which hedge fund is a major shareholder of Celcuity Inc.?
Currently, no hedge funds are holding shares in CELC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celcuity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$161.75 (32.08% Upside)
$161.75 (32.08% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
687.38%
12-Months-Change
Fundamentals
Return on Equity
-244.61%
Trailing 12-Months
Asset Growth
88.04%
Trailing 12-Months
Company Description
Celcuity Inc.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
CELC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was clinically very positive: robust Phase III efficacy signals in both wild-type and mutant cohorts, expansion into first-line studies, promising prostate cancer combo data, IP and formulation work for a subcutaneous version, and a staffed commercial organization targeting a large (~$5B+) second-line market and potential peak revenues up to $2.5B. Offsetting these achievements are materially higher losses and cash burn (net loss up ≈43%, non-GAAP loss up ≈35%, operating cash use up ≈54%), a large increase in SG&A (≈176%), runway that extends through 2027 only with debt drawdowns, and regulatory/clinical timelines (notably first-line data by 2028–2030 and potential additional studies for subcutaneous formulation) that delay broader commercialization. On balance, strong clinical progress and commercial preparations outweigh the near-term financial and timing challenges, but the company will need to manage cash and regulatory requirements closely.View all CELC earnings summariesCELC Stock 12 Month Forecast
Average Price Target
$161.75
▲(32.08% Upside)
Technical Analysis
―
IDEAYA Biosciences
―
Tarsus Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Apogee Therapeutics
―
Ownership Overview
24.35% Insiders
11.80% Mutual Funds
9.67% Other Institutional Investors
44.16% Public Companies and Individual Investors
Options Prices
Currently, No data available
---